The ENZA-p trial analyzed the activity and safety of enzalutamide with [177Lu]Lu-PSMA-617 (a radiopharmaceutical containing prostate-specific membrane antigen) versus enzalutamide alone as a first-line treatment for metastatic castration-resistant prostate cancer (mCRPC). New data have elaborated on the study’s findings along with additional follow-up information. ...
CRPC
![ENZA-p Trial: Enzalutamide With [177Lu]Lu-PSMA-617 Improves OS in mCRPC](https://mumcdnstorage.blob.core.windows.net/guonc/2022/12/Prostate-3.0.png)
Advertisement
Latest News
Dr. Tan discusses the TALAPRO-2 study, PARP inhibitor synergy, HRR testing, and evolving treatment strategies in mCRPC.
The combination demonstrated a manageable safety profile with evidence of EZH2 pharmacodynamic inhibition and OR.
Final TALAPRO-2 results show talazoparib + enzalutamide significantly improves survival in patients with HRR-deficient mCRPC.
New research sheds light on the real-world outcomes of Lu-PSMA-617 in a racially diverse patient population.
Tala/enza demonstrated improvement in OS compared with enza alone as 1L treatment in patients with mCRPC.
C2D1 ctDNA fraction may be more strongly associated with rPFS and OS than baseline ctDNA fraction.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.
Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.
Drs. Tawagi and Armstrong recap the hottest topics in kidney cancer research from the 2025 ASCO GU Cancers Symposium.
Dr. Sonpavde provides an update on the latest analysis from the phase 3 global study of EV in combination with pembro.
Advertisement
Advertisement
Latest News
Dr. Tan discusses the TALAPRO-2 study, PARP inhibitor synergy, HRR testing, and evolving treatment strategies in mCRPC.
A recent proof-of-concept study has further evaluated the efficacy of PSMA-guided MDT for oligometastatic RCC.
COSMIC-021 began in 2017 to analyze the effects of cabozantinib alone or with atezolizumab for advanced solid tumors.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.